SEC Contract Filing

Filing Date: 2021-11-04

Document Content:
<DOCUMENT>
<TYPE>EX-10.1
<SEQUENCE>2
<FILENAME>d254551dex101.htm
<DESCRIPTION>EX-10.1
<TEXT>
<HTML><HEAD>
<TITLE>EX-10.1</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B>Exhibit 10.1 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>Certain information identified by &#147;[*]&#148; has been excluded in this document because it is </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>both (i)&nbsp;not material and (ii)&nbsp;would be competitively harmful if publicly disclosed. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="right"><B><I>Execution Copy </I></B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUSIVE LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>by and between </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>HANMI
PHARMACEUTICAL CO. LTD. </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>and </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>APTOSE BIOSCIENCES INC. </B></P>
</DIV></Center>

<p style="margin-top:1em; margin-bottom:0em; page-break-before:always">
<HR SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">

<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>EXCLUSIVE LICENSE AGREEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">This Agreement is effective as of November&nbsp;4, 2021, (the <B>&#147;Effective Date&#148;</B>) and is entered into by and between HANMI
PHARMACEUTICAL CO. LTD., a corporation organized and existing under the laws of the Republic of Korea (<B>&#147;Hanmi&#148;</B>) and APTOSE BIOSCIENCES INC., a corporation organized and existing under the laws of Ontario, Canada
(<B>&#147;Aptose&#148;</B>). </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>RECITALS: </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, Hanmi has developed Hanmi <FONT STYLE="white-space:nowrap">Know-How</FONT> (as hereinafter defined) and has rights to Hanmi
Patent Rights (as hereinafter defined); </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS</B>, Hanmi has conducted a research and development program on the Compounds and
Products (as hereinafter defined) and; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>WHEREAS, </B>Aptose desires to obtain a license under the Hanmi Patent Rights and Hanmi <FONT
STYLE="white-space:nowrap">Know-How</FONT> upon the terms and conditions set forth herein, and Hanmi desires to grant such a license; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>NOW, THEREFORE, </B>in consideration of the foregoing premises and the mutual covenants contained herein, the receipt and sufficiency of
which are hereby acknowledged, Hanmi and Aptose hereby agree as follows: </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>ARTICLE 1 DEFINITIONS. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify">Unless specifically set forth to the contrary herein, the following terms, whether used in the singular or plural, shall have the respective
meanings set forth below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.1</B> <B>&#147;Acceptance&#148; </B>shall mean, with respect to an NDA, the receipt by Aptose of a letter
from the FDA with respect to such NDA indicating that such NDA has been accepted for filing and further FDA review (or any equivalent indication of acceptance thereof in the event of a change in the procedures used by the FDA). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.2</B> <B>&#147;Act&#148; </B>shall mean, as applicable, the United States Federal Food, Drug and Cosmetic Act, 21 U.S.C. &#167;&#167; 301
et seq., or the Public Health Service Act, 42 U.S.C. &#167;&#167; 262 et seq., as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.3</B> &#147;<B>Active
Pharmaceutical Ingredient</B>&#148; means a clinically active material that provides pharmacological activity in a pharmaceutical product when administered to a subject (excluding formulation components such as coatings, stabilizers, excipients or
solvents, adjuvants or controlled release technologies and delivery technologies). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="justify"><B>1.4</B> <B>&#147;Affiliate&#148; </B>shall mean,
with respect to each party, (a)&nbsp;any corporation or business entity more than fifty percent (50%) of the voting stock or voting equity interests of which are owned directly or indirectly by such party; or (b)&nbsp;any corporation or business
entity which directly or indirectly owns more than fifty percent (50%) of the voting stock or voting equit